Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab

Kevin Windebank, Tom Walwyn, Richard Kirk, Gareth Parry, Asif Hasan, Nick Bown, Bridget Wilkins

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Background. Post-transplant lymphoproliferative disorder (PTLD) occasionally presents as Burkitt lymphoma/L3 leukaemia (BLL). Procedure. We reviewed records of cases of PTLD post-cardiac transplantation (1990-2007) occurring in our unit. Results. There were 15 episodes in 13 patients including four cases of EBV-driven Burkitt-type disease with t(8;14) translocations presenting with advanced stage disease. The first case was treated with a variety of low dose chemotherapy combinations. Despite problems during therapy he obtained complete remission, but died from complications of pre-existing cardiac allograft vasculopathy 7 months later. The subsequent three cases were treated with a UKCCSG low stage lymphoma protocol, NHL 9001 and Rituximab. They remain in complete remission. Conclusions. In the context of PTLD the prognostic significance of advanced stage EBV-driven BLL with the t(8;14) translocation may be different to that in immunocompetent children.

Original languageEnglish (US)
Pages (from-to)392-396
Number of pages5
JournalPediatric Blood and Cancer
Volume53
Issue number3
DOIs
StatePublished - Sep 1 2009

Keywords

  • Burkitt lymphoma
  • Epstein-Barr virus
  • Immunocompromised host
  • Immunotherapy
  • Transplantation
  • Tumour biology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab'. Together they form a unique fingerprint.

  • Cite this